Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesX4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.23 USD -0.01 ( 0.46%)
Last update at 2026-11-11T21:00:00Z
VOLUME
775460
Market Cap
358.91M
P/E
2.53

Momentum Score

…

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.17
Low
3.36
High
52 Week Price Range
2.80
Low
4.83
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

X4 Pharmaceuticals is a clinical-stage biotech developing oral modulators of the CXCR4 chemokine receptor for rare immunology and oncology indications. Long-term growth may come from positive clinical data, expanded indications, and partnerships that could support commercial opportunities in defined patient populations.
Material risks include clinical and regulatory trial failure, lack of product revenue and consequent financing or dilution risk, and reliance on a small pipeline and partnerships.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.25
Dividend Yield
-
Revenue TTM
15.85M
Revenue Per Share
0.16
Gross Profit TTM
12.92M
Debt / Equity
0.41
ROE
-113.08%
Net Debt
-139.76M
ROCE
-26.55%
Diluted EPS TTM
1.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -79.16M -37.14M -101.09M -93.84M -88.68M
Net income -79.20M -37.45M -101.17M -93.87M -88.70M
Selling general administrative 43.52M 61.52M 32.14M 27.02M 24.70M
Gross profit 28.86M 1.76M -2.00M - -
Reconciled depreciation 1.28M 0.80M 0.48M 0.51M 0.50M
Ebit -70.28M -28.37M -95.31M -87.57M -85.11M
Ebitda -69.00M -27.58M -94.89M -88.59M -65.59M
Depreciation and amortization 1.28M 0.80M 0.42M -1.02M 19.52M
Non operating income net other - - - -2.28M -
Operating income -86.88M -36.40M -107.52M -87.57M -85.11M
Other operating expenses 122.00M 38.96M 107.52M 88.08M 75.35M
Interest expense 8.88M 8.77M 5.78M 3.99M 3.64M
Tax provision 0.04M 0.31M 0.06M 0.03M 0.02M
Interest income 4.58M 5.77M 3.33M 0.22M 0.01M
Net interest income -4.30M -3.00M -1.70M -3.77M -3.63M
Income tax expense 0.04M 0.31M 0.08M 0.03M 0.02M
Total revenue 35.11M 2.56M 0.00M 0.00M 0.00M
Total operating expenses 115.74M 38.16M 107.52M 88.08M 75.35M
Cost of revenue 6.26M 0.80M 2.00M - -
Total other income expense net 7.72M -0.74M 6.43M -6.27M -3.57M
Net income from continuing ops -79.20M -37.45M -111.14M -93.87M -88.70M
Net income applicable to common shares - - - -96.41M -102.64M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 290.46M 146.45M 147.26M 155.59M 117.18M
Intangible assets 9.25M 10.00M - - -
Other current assets 3.53M 5.59M 7.05M 5.81M 5.34M
Total liab 104.17M 124.30M 96.16M 81.53M 52.76M
Total stockholder equity 186.29M 22.15M 51.10M 74.05M 64.41M
Deferred long term liab - - - 23.13M -
Other current liab 18.60M 23.00M 12.82M 12.03M 7.87M
Common stock 0.09M 0.01M 0.17M 0.12M 0.03M
Capital stock 0.09M 0.17M 0.17M 0.12M 0.03M
Retained earnings -594.55M -515.36M -477.90M -376.74M -282.87M
Other liab - - - 23.30M 0.83M
Good will 17.35M 17.35M 17.35M 17.35M 17.35M
Other assets - - 0.00M 1.23M 1.72M
Cash 217.05M 55.70M 99.47M 121.72M 81.79M
Total current liabilities 25.76M 32.88M 22.86M 22.32M 14.02M
Current deferred revenue 0.46M - - - -
Net debt -139.76M 22.39M -41.19M -83.30M -42.00M
Short term debt 0.99M 1.25M 1.10M 2.51M 1.87M
Short long term debt - - - 1.31M 0.80M
Short long term debt total 77.28M 78.09M 58.28M 38.42M 39.78M
Other stockholder equity 780.86M 537.62M 528.96M 450.79M 347.37M
Property plant equipment - - - 1.10M 10.22M
Total current assets 261.58M 112.17M 122.08M 128.68M 87.88M
Net tangible assets - - - 56.70M 47.06M
Short term investments 35.95M 46.36M 15.00M - -
Net receivables 0.57M 1.71M 0.56M 1.15M 0.75M
Long term debt 76.29M 75.42M 54.57M 32.30M 33.14M
Inventory 4.48M 2.82M - - -0.75M
Accounts payable 5.70M 8.62M 8.95M 7.78M 4.28M
Accumulated other comprehensive income -0.11M -0.12M -0.12M -0.12M -0.12M
Common stock total equity - - - 0.12M -
Retained earnings total equity - - - -376.74M -
Non currrent assets other 0.69M 2.08M 0.65M 1.23M 1.72M
Non current assets total 28.88M 34.27M 25.18M 26.91M 29.30M
Capital lease obligations 0.99M 2.66M 3.71M 4.80M 5.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 11.15M 66.99M -10.08M -0.10M -0.61M
Change to liabilities - - - 7.23M 1.17M
Total cashflows from investing activities 8.15M 66.99M -14.88M -0.10M -0.61M
Net borrowings 0.00M 20.00M 20.44M -0.80M -
Total cash from financing activities 238.63M 20.29M 88.52M 117.23M 74.25M
Change to operating activities - - - 5.74M -1.50M
Net income -79.20M -37.45M -101.17M -93.87M -88.70M
Change in cash 161.38M -43.77M -22.78M 39.92M 2.41M
Begin period cash flow 56.48M 100.25M 123.03M 83.11M 80.70M
End period cash flow 217.85M 56.48M 100.25M 123.03M 83.11M
Total cash from operating activities -85.62M -130.90M -96.51M -77.10M -70.91M
Issuance of capital stock 238.53M 0.00M 122.01M 122.63M 75.98M
Depreciation 1.28M 0.80M 0.42M 0.51M 0.50M
Other cashflows from investing activities -3.00M 98.00M - -0.10M -0.61M
Dividends paid - - - - 13.94M
Change to inventory -1.66M -2.82M 0.00M - -
Change to account receivables 0.50M -1.07M -1.37M - -
Sale purchase of stock - - 0.00M 0.21M -2.00M
Other cashflows from financing activities 0.10M 0.29M 8.08M -4.61M 0.26M
Change to netincome - - - 6.15M 19.29M
Capital expenditures 3.00M 7.33M 0.06M 0.10M 0.61M
Cash flows other operating - - - 2.87M -
Cash and cash equivalents changes - - - 40.02M -
Change in working capital -2.58M 2.67M 0.34M 5.74M -1.50M
Stock based compensation 4.30M 8.20M 8.69M 5.20M 6.18M
Other non cash items -9.42M -105.13M -4.79M 5.32M 19.29M
Free cash flow -88.62M -138.23M -96.57M -77.20M -71.52M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
XFOR
X4 Pharmaceuticals Inc		 -0.01
0.46%		 3.23 2.53 - 22.65 2.31 14.40 1.10
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

61 North Beacon Street, Boston, MA, United States, 02134

857 529 8300

https://www.x4pharma.com

45

Name Title Year Born
Dr. Paula Ragan Ph.D. Founder, CEO, Pres, Sec. & Director 1971
Mr. Adam S. Mostafa CFO, Treasurer & Assistant Sec. 1980
Dr. Murray W. Stewart M.D. Interim Chief Medical Officer & Director 1961
Dr. Richard Peters M.D., Ph.D. Founder 1963
Dr. Renato T. Skerlj Ph.D. Founder NA
Dr. Keith T. Flaherty M.D. Founder & Member of Corp. Advisory Board 1971
Dr. Mary DiBiase Ph.D. Chief Operating Officer 1961
Dr. Arthur Taveras Ph.D. Chief Scientific Officer 1964
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. VP of Investor Relations & Corp. Communications NA
Dr. Robert David Arbeit Sr. VP of Clinical Devel. and Translational Research 1948

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…